Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
129.06
+9.13 (7.61%)
At close: Apr 24, 2026, 4:00 PM EDT
128.95
-0.11 (-0.09%)
After-hours: Apr 24, 2026, 7:46 PM EDT
Inhibrx Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Ozekibart plus FOLFIRI showed a 20% ORR and 5.5-month median PFS in late-line CRC, with durable responses and a favorable safety profile. Plans are underway for first-line registrational trials and expansion into earlier lines and other tumor types.
Fiscal Year 2025
-
Ozekibart showed significant efficacy in chondrosarcoma, doubling PFS and reducing risk of progression or death by 52%. Promising response rates were also seen in late-line colorectal cancer and Ewing sarcoma, with a combined market potential exceeding $2.5 billion.